Southern Cancer Center

Daphne, Alabama 36526

5 studies enrolling now · 13 studies all time

What they study most

Cancer, Diffuse Large B-Cell Lymphoma, Early Breast Cancer, Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer, KEAP1 Gene Mutation, Limited Stage Small Cell Lung Cancer, Metastatic Pancreas Adenocarcinoma, NFE2L2 Gene Mutation, NRF2 Mutation, Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Carcinoma

Studies at this site

• A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer) — Recruiting now
• A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC) — Recruiting now
• A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer — Recruiting now
• BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS) — Recruiting now
• Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic Adenocarcinoma — Available (expanded access)
• A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer) — Running, not enrolling
• A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma — Completed
• INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma — Stopped early
• A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101) — Completed
• Development and Validation of Harbinger Health Test for Early Cancer Detection — Completed
• Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC (KICKSTART) — Status unconfirmed
• NGS Screening Protocol to Detect Mutation of KEAP1 or NRF2/NFE2L2 Genes for the KEAPSAKE (CX-839-014) Trial — Stopped early
• Expanded Access Study of Alectinib for Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) After Disease Progression on or Intolerance to Prior ALK Tyrosine Kinase Inhibitor Therapy — NO_LONGER_AVAILABLE